| Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer L Ma, MO Hernandez, Y Zhao, M Mehta, B Tran, M Kelly, Z Rae, ... Cancer cell 36 (4), 418-430. e6, 2019 | 487 | 2019 |
| Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma L Ma, L Wang, SA Khatib, CW Chang, S Heinrich, DA Dominguez, ... Journal of hepatology 75 (6), 1397-1408, 2021 | 148 | 2021 |
| Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma Q Zhang, C Ma, Y Duan, B Heinrich, U Rosato, LP Diggs, L Ma, S Roy, ... Cancer discovery 11 (5), 1248-1267, 2021 | 140 | 2021 |
| Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma MH Hung, JS Lee, C Ma, LP Diggs, S Heinrich, CW Chang, L Ma, ... Nature communications 12 (1), 1455, 2021 | 114 | 2021 |
| Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis S Heinrich, AJ Craig, L Ma, B Heinrich, TF Greten, XW Wang Journal of Hepatology 74 (3), 700-715, 2021 | 71 | 2021 |
| PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma SP Martin, V Fako, H Dang, DA Dominguez, S Khatib, L Ma, H Wang, ... Journal of Experimental & Clinical Cancer Research 39, 1-15, 2020 | 60 | 2020 |
| Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis Y Liu, S Zhuo, Y Zhou, L Ma, Z Sun, X Wu, XW Wang, B Gao, Y Yang Journal of hepatology 76 (3), 652-664, 2022 | 48 | 2022 |
| Intratumoral γδ T‐cell infiltrates, chemokine (C‐C Motif) ligand 4/chemokine (C‐C Motif) ligand 5 protein expression and survival in patients with hepatocellular carcinoma N Zhao, H Dang, L Ma, SP Martin, M Forgues, K Ylaya, SM Hewitt, ... Hepatology 73 (3), 1045-1060, 2021 | 46 | 2021 |
| Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer L Ma, S Heinrich, L Wang, FL Keggenhoff, S Khatib, M Forgues, M Kelly, ... Nature Communications 13 (1), 7533, 2022 | 41 | 2022 |
| EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib L Ma, DD Wang, Y Huang, H Yan, MP Wong, VHF Lee BMC bioinformatics 16, 1-10, 2015 | 40 | 2015 |
| Immunology and immunotherapy of cholangiocarcinoma TF Greten, R Schwabe, N Bardeesy, L Ma, L Goyal, RK Kelley, XW Wang Nature Reviews Gastroenterology & Hepatology 20 (6), 349-365, 2023 | 39 | 2023 |
| Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib-and erlotinib-resistance in non-small-cell lung carcinoma treatments DD Wang, L Ma, MP Wong, VHF Lee, H Yan PloS one 10 (5), e0128360, 2015 | 38 | 2015 |
| Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations B Zou, VHF Lee, L Chen, L Ma, DD Wang, H Yan Scientific reports 7 (1), 1-13, 2017 | 36 | 2017 |
| A phase II study of pembrolizumab in combination with capecitabine and oxaliplatin with molecular profiling in patients with advanced biliary tract carcinoma C Monge, EC Pehrsson, C Xie, AG Duffy, D Mabry, BJ Wood, DE Kleiner, ... The oncologist 27 (3), e273-e285, 2022 | 24 | 2022 |
| Single-cell gene expression analysis reveals β-cell dysfunction and deficit mechanisms in type 2 diabetes L Ma, J Zheng BMC bioinformatics 19, 37-48, 2018 | 20 | 2018 |
| Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin B Ruf, M Bruhns, S Babaei, N Kedei, L Ma, M Revsine, MR Benmebarek, ... Cell 186 (17), 3686-3705. e32, 2023 | 18 | 2023 |
| An eigen-binding site based method for the analysis of anti-EGFR drug resistance in lung cancer treatment L Ma, DD Wang, B Zou, H Yan IEEE/ACM transactions on computational biology and bioinformatics 14 (5 …, 2016 | 18 | 2016 |
| Boolean network modeling of β-cell apoptosis and insulin resistance in type 2 diabetes mellitus P Dutta, L Ma, Y Ali, PMA Sloot, J Zheng BMC systems biology 13, 1-12, 2019 | 16 | 2019 |
| Hypoxia is a key regulator in liver cancer progression L Ma, AJ Craig, S Heinrich Journal of hepatology 75 (3), 736-737, 2021 | 14 | 2021 |
| Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics L Ma, B Zou, H Yan Proteome science 14, 1-9, 2016 | 14 | 2016 |
Tim GretenNational Cancer InstituteGeverifieerd e-mailadres voor nih.gov
